An analysis of COVID-19 vaccination progress and the number of vaccines in use around the world shows that relying on a high number of vaccines can have positive effects in the fight against the coronavirus pandemic.
Most countries around the world have only authorized a single vaccine so far, among them most low-income countries which rely on the COVAX initiative’s supply of the AstraZeneca vaccine. Middle income countries which are using two or three vaccine types typically had better success in progressing their vaccination campaigns than those using only one vaccine.
While high income countries predictably did better in their campaigns, few authorized more than three vaccines and most relied on the combination of the Moderna, Pfizer and AstraZeneca varieties. There seems to be some kind of glass ceiling, however, for most high-income countries and few had surpassed 25 vaccine doses per 100 of population by early April. The countries which authorized four or more vaccines – thereby combining Chinese, Russian, European and American types – achieved much better results in general. Serbia, an upper-middle income country following this approach, had already given out almost 40 vaccine doses per 100 of its population in early April. Hungary, a high-income country, achieved almost as many.
The United Arab Emirates, the only country to have authorized five vaccine types so far, had the most successful vaccination campaign at almost 90 doses per 100 of its population behind Israel, which served as a model region for the Pfizer vaccine and is therefore excluded from the chart.
This chart shows countries by number of vaccine doses given out per 100 of population and number of vaccines fully authorized.
Wall Street Examiner Disclosure: Lee Adler, The Wall Street Examiner reposts third party content with the permission of the publisher. The opinions expressed in these reposts are not those of the Wall Street Examiner or Lee Adler, unless authored by me, under my byline. I curate posts here on the basis of whether they represent an interesting and logical point of view, that may or may not agree with my own views. Some of the content includes the original publisher's promotional messages. No endorsement of such content is either expressed or implied by posting the content. All items published here are matters of information and opinion, and are neither intended as, nor should you construe it as, individual investment advice. Do your own due diligence when considering the offerings of information providers, or considering any investment.